Global health and foreign policy: accelerating the fight against diseases driven by social determinants of health A/RES/80/265 Quadripartite organizations, namely, the World Health Organization, the Food and Agriculture Organization of the United Nations, the World Organization for Animal Health and the United Nations Environment Programme, Seriously concerned that the supply of health products and technologies is dependent on manufacturing facilities concentrated in few countries and that the lack of national or regional production capacities, adequate infrastructure and logistics expertise to store, distribute and deliver diagnostics, medicines, vaccines and other health products and technologies, particularly in developing countries, among other factors, hampers efforts to achieve diagnosis, treatment and vaccination targets for several diseases, at the right time, safely and efficiently, especially in the context of health emergencies, Encouraging the promotion of increased access to affordable, safe, effective and quality medicines, including generics, vaccines, diagnostics and health technologies, reaffirming the World Trade Organization Agreement on Trade -Related Aspects of Intellectual Property Rights (TRIPS Agreement) as amended, and also reaffirming the 2001 World Trade Organization Doha Declaration on the TRIPS Agreement and Public Health, which recognizes that intellectual property rights should be interpreted and implemented in a manner supportive of the right of Member States to protect public health and, in particular, to promote access to medicines for all, and noting the need for appropriate incentives in the development of new health products, Reaffirming the right to use, to the fullest extent, the provisions contained in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), which provides flexibilities for the protection of public health and promotes access to medicines for all, in particular for developing countries, and the World Trade Organization Doha Declaration on the TRIPS Agreement and Public Health, which recognizes that intellectual property protection is important for the development of new medicines and also recognizes the concerns about its effects on prices, while noting the discussions in the World Trade Organization and other relevant international forums, including on innovative options to enhance the global effort towards the production and timely and equitable distribution of COVID‑19 vaccines, therapeutics, diagnostics and other health technologies, including through local production, and noting the outcome of the Twelfth Ministerial Conference of the World Trade Organization, including the ministerial decision on the TRIPS Agreement and the ministerial declaration on the World Trade Organization response to the COVID‑19 pandemic and preparedness for future pandemics, Expressing deep concern about the persistent lack of equity in access, both between and within countries, especially of developing countries, and particularly African countries, to safe, quality, efficacious, effective and affordable vaccines, therapeutics and diagnostics against infectious diseases, emphasizing the need to enhance the capacities of developing countries to achieve universal health coverage, have equitable access to vaccines, health technologies and means to prevent, respond to and recover from health emergencies, reaffirming the need to strengthen the support for national, regional and multilateral initiatives that aim to accelerate the development and geographically diversified production of and equitable access to diagnostics, therapeutics and vaccines, and taking note of the Declaration on the Right to Development, 13 Welcoming the adoption by the World Health Assembly at its seventy-eighth session of the World Health Organization Pandemic Agreement, which strengthens the pandemic prevention, preparedness and response legal framework, looking _______________ 13 6/10 Resolution 41/128, annex. 26-07986